FDA Grants Orphan Drug Status to Auris’ Intranasal Betahistine for Treatment of PWS-linked Obesity
The U.S. Food and Drug Administration has granted an orphan drug designation to Auris Medical for its intranasal betahistine product for the treatment of obesity associated with Prader-Willi syndrome. In addition to Prader-Willi syndrome, the company also has plans to expand the betahistine development program to include depression…